Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RobinHood Markets, Inc. (NASDAQ: HOOD), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), Landstar System, Inc. (NASDAQ: LSTR), and ICU Medical, Inc. (NASDAQ: ICUI). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

RobinHood Markets, Inc. (NASDAQ: HOOD)

On March 7, 2025, the Financial Industry Regulatory Authority ("FINRA") announced that it "has ordered Robinhood Financial to pay $3.75 million to its customers, and fined Robinhood Financial and Robinhood Securities $26 million for violating numerous FINRA rules, including failing to respond to red flags of potential misconduct." FINRA accused Robinhood of giving customers inaccurate or incomplete disclosures associated with its practice of so-called "collaring" market order by converting them to limit orders and found that the trading platform failed to create and implement "reasonable anti-money laundering programs, which caused the firms to fail to detect, investigate or report suspicious activity, including manipulative trading, suspicious money movements and instances where customers' accounts were taken over by third-party hackers." On this news, Robinhood's stock price fell $8.79 per share, or 19.79%, to close at $35.63 per share on March 10, 2025.

For more information on the Robinhood investigation go to: https://bespc.com/cases/HOOD

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)

On April 3, 2025, Aldeyra issued a press release "announc[ing] receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease." The press release specified that "[a]lthough no manufacturing or safety issues with reproxalap were identified, the FDA stated in the letter that the NDA ‘failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes' and that ‘at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye' should be conducted." The press release further stated that "[t]he letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms." On this news, Aldeyra's stock price fell sharply during intraday trading on April 3, 2025.

For more information on the Aldeyra investigation go to: https://bespc.com/cases/ALDX

Landstar System, Inc. (NASDAQ: LSTR)

On April 2, 2025, Landstar revealed that it had "identified a significant supply chain fraud." The Company said "this fraud may adversely affect Landstar's 2025 first quarter earnings per share in a range of $0.35 to $0.50." As a result, Landstar withdrew its previously issued first quarter 2025 earnings guidance. Following this news, Landstar stock dropped. Then, on April 25, 2025, Landstar announced that it would be unable to timely file its quarterly report as it had not yet completed its ongoing evaluation of certain accounting and internal control matters related to the previously identified fraud. Following this news, Landstar stock again dropped, thereby damaging investors.

For more information on the Landstar investigation go to: https://bespc.com/cases/LSTR

ICU Medical, Inc. (NASDAQ: ICUI)

On April 22, 2025, ICU disclosed receipt of a warning letter from the U.S. Food and Drug Administration (“FDA”), citing unauthorized changes to two of the Company’s infusion pump products.  The FDA’s warning letter stated that the pumps were “adulterated” and “misbranded,” noting that the Company's modifications “can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, [and] alarm functionality.”  The FDA further stated that these changes may have significantly impacted the safety and efficacy of the devices, raising concerns about the adequacy of ICU’s regulatory disclosures.

On this news, ICU’s stock price fell $6.04 per share, or 4.42%, to close at $130.68 per share on April 22, 2025.

For more information on the ICU Medical investigation go to: https://bespc.com/cases/ICUI

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.